Bulk Anti-Human CD2 (LO-CD2a) In Vivo Antibody

LO-CD2a strongly inhibits mixed lymphocyte culture (MLC) 3 and induces T cell apoptosis. Additionally, LO-CD2a does not induce proliferation of resting T cells, and inhibits T cell proliferation induced by OKT3 antibody, induces very low levels of cytokine release, and also inhibits cytokine production induced by OKT3, LO-CD2a strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3, and induces human T cell hyporesponsiveness. Adding LO-CD2a to a primary MLC inhibits the T cell proliferation response and has a subsequent inhibitory effect on the secondary immune response, thereby blocking primary and memory alloantigen proliferative responses. The human T cell hyporesponsiveness in the secondary MLC is restricted to alloantigens and occurs both in the absence of antibody and after cell surface re-expression of CD2

BTI-322, CD2, CD2 molecule, T11, SRBC, LFA-2, T-cell surface antigen CD2, LFA-3 receptor, rosette receptor, erythrocyte receptor, lymphocyte-function antigen-2, T-cell surface antigen T11/Leu-5, CD2 antigen (p50), sheep red blood cell receptor

LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation. LO-CD2a was produced by immunizing a LOU/C rat with purified human T lymphocytes and fusing the splenocytes with the non-secreting rat fusion cell line IR983F, resulting in a rat IgG2b mAb of the IgK-1a allotype

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.